Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZYMEWORKS INC.

(ZYME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zymeworks to Get Milestone Payment After Janssen Doses First Patient With Licensed Antibody

12/01/2021 | 10:21am EST


ę MT Newswires 2021
All news about ZYMEWORKS INC.
01/20Zymeworks to Cut 10 Senior Executives, Reduce Workforce by 25% in 2022; Stock Slumps Th..
MT
01/19Zymeworks to Cut 10 Senior Executives, Reduce Workforce by 25% in 2022; Stock Down 3% L..
MT
01/19ZYMEWORKS : Provides Corporate Update on Key Strategic Priorities and Outlook for 2022 - F..
PU
01/19ZYMEWORKS INC. : Results of Operations and Financial Condition, Costs Associated with Exit..
AQ
01/19Zymeworks Inc. Announces Management Changes
CI
01/19Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
BU
01/18ZYMEWORKS : Reports Inducement Grant Under New York Stock Exchange Listed Company Manual R..
PU
01/18ZYMEWORKS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/17Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual ..
AQ
01/15Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual ..
BU
More news
Analyst Recommendations on ZYMEWORKS INC.
More recommendations
Financials (USD)
Sales 2021 15,1 M - -
Net income 2021 -234 M - -
Net cash 2021 215 M - -
P/E ratio 2021 -2,55x
Yield 2021 -
Capitalization 538 M 538 M -
EV / Sales 2021 21,3x
EV / Sales 2022 9,58x
Nbr of Employees 455
Free-Float 91,2%
Chart ZYMEWORKS INC.
Duration : Period :
Zymeworks Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZYMEWORKS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 11,55 $
Average target price 43,86 $
Spread / Average Target 280%
EPS Revisions
Managers and Directors
Ali Tehrani President, Chief Executive Officer & Director
Neil Klompas Chief Operating & Financial Officer
Lota S. Zoth Chairman
Anthony J. Polverino Chief Scientific Officer & EVP-Early Development
Mark Hollywood Senior VP-Technical & Manufacturing Operations
Sector and Competitors
1st jan.Capi. (M$)
ZYMEWORKS INC.-29.53%538
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-9.18%51 206
BIONTECH SE-39.28%37 805